« ACRYSOF Single-Piece Posterior Chamber Intraocular Lenses With Toric Optic, Models | Main | FDA Approvals - BioBalance Corporation to Present at Rodman & Renshaw Healthcare Conference »

SkyePharma and Kos Announce Exclusive Licence Agreement for Marketing and


SkyePharma and Kos Announce Exclusive Licence Agreement for Marketing and Distribution of Flutiform(TM) in the United (PR Newswire via Yahoo! Finance)
SkyePharma PLC announces today that it has entered into an agreement with Kos Pharmaceuticals, Inc. to jointly develop Flutiform, SkyePharma's novel combination product for asthma and chronic obstructive pulmonary disease .

ePharmaceuticals Launches Drug Safety Newsletter (PR Web)
ePharmaceuticals, a division of healthcare regulatory publisher HCPro, has launched of Briefings on Drug Safety, a monthly electronic newsletter that will provide information and guidance to help pharmaceutical professionals make smart drug safety, risk management, and marketing decisions. (PRWEB May 8, 2006) Trackback URI: http://www.prweb.com/zingpr.php/SGFsZi1UaGlyLUhhbGYtRmFsdS1IYWxmLVplcm8=

Software QC Module is suited for life sciences companies. (ThomasNet)
Able to function as stand-alone application or part of integrated NetRegulus NetRM(TM) quality management solutions suite, NetRegulus NetRM(TM) CAPA (Corrective and Preventive Action) module provides quality management capabilities that let users initiate, evaluate, assign, monitor, review, and approve each CAPA record. This enterprise regulatory data management module, configurable to unique
 

©2006 FDA-News.com. All rights reserved.